共 50 条
- [1] Phase II study of evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancerANNALS OF ONCOLOGY, 2018, 29Yoon, J. S.Lee, K-H.Cheon, G. J.Bang, Y-J.Oh, D-Y.
- [2] Phase I study of pazopanib plus TH-302 in advanced solid tumorsCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 611 - 619Riedel, Richard F.Meadows, Kellen L.Lee, Paula H.Morse, Michael A.Uronis, Hope E.Blobe, Gerard C.George, Daniel J.Crawford, JeffreyNiedzwiecki, DonnaRushing, Christel N.Arrowood, Christy C.Hurwitz, Herbert I.
- [3] Phase I study of pazopanib plus TH-302 in advanced solid tumorsCancer Chemotherapy and Pharmacology, 2017, 79 : 611 - 619Richard F. RiedelKellen L. MeadowsPaula H. LeeMichael A. MorseHope E. UronisGerard C. BlobeDaniel J. GeorgeJeffrey CrawfordDonna NiedzwieckiChristel N. RushingChristy C. ArrowoodHerbert I. Hurwitz
- [4] Efficient synthesis of 2-nitroimidazole derivatives and the bioreductive clinical candidate Evofosfamide (TH-302)Organic Chemistry Frontiers, 2015, 2 (09): : 1026 - 1029O'Connor, Liam J.Cazares-Koerner, CindySaha, JaideepEvans, Charles N. G.Stratford, Michael R. L.Hammond, Ester M.Conway, Stuart J.
- [5] Japanese phase I trial of hypoxia-activated prodrug evofosfamide (TH-302) as monotherapy in patients with solid tumors or in combination with gemcitabine in patients with advanced pancreatic cancerEUROPEAN JOURNAL OF CANCER, 2015, 51 : S436 - S436Mitsunaga, S.Takahashi, H.Doi, T.Johne, A.Wang, J.Shimizu, A.Ikeda, M.
- [6] PHASE II STUDY OF GEMCITABINE + TH-302 VS GEMCITABINE ALONE IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC PANCREATIC CANCERANNALS OF ONCOLOGY, 2012, 23 : 8 - 8Ryan, D.Reddy, S.Bahary, N.Uronis, H.Sigal, D. S.Cohn, AllenSchelman, W. R.Chiorean, E. G.Rosen, P. J.Ulrich, B.Dragovich, T.Del Prete, S.Rarick, M.Eng, C.Kroll, S.
- [7] Phase I/II study of TH-302 in combination with gemcitabine in patients with solid tumors including advanced pancreatic cancer.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Schelman, W. R.Borad, M. J.Chiorean, E. G.Mita, A. C.Vlahovic, G.Mendelson, D. S.Langmuir, V. K.Eng, C.Kroll, S.Bendell, J. C.
- [8] Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemiasJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Konopleva, MarinaHandisides, DamianLorente, Gustavo A.Benito, Juliana M.Richie, Mary AnnBorthakur, GautamJabbour, EliasFaderl, StefanCortes, Jorge E.Kroll, StewartAndreeff, MichaelKantarjian, HagopThomas, Deborah A.
- [9] Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid MalignanciesCLINICAL CANCER RESEARCH, 2011, 17 (09) : 2997 - 3004Weiss, Glen J.Infante, Jeffrey R.Chiorean, E. GabrielaBorad, Mitesh J.Bendell, Johanna C.Molina, Julian R.Tibes, RaoulRamanathan, Ramesh K.Lewandowski, KarenJones, Suzanne F.Lacouture, Mario E.Langmuir, Virginia K.Lee, HankKroll, StewBurris, Howard A., III
- [10] Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced ns-NSCLCJOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S553 - S553Goldman, Jonathan W.Bennett, CharlesCarter, CoreyCiuleanu, TudorColeman, MortonCsoszi, TiborDe Marinis, FilippoGarcia Gomez, RamonKrakowski, MaciejMolina, JulianNovello, SilviaOrlov, SergeiOstoros, GyulaPalmer, RobertRobert, FranciscoStella, PhilipVon Pawel, JoachimPearce, TillmanKroll, StewBelani, Chandra P.